Cover Image

ANTI-TUMOR POTENTIAL OF CASSIA FISTULA LINN.: A PHYTOCHEMICAL AND PRECLINICAL STUDY ON DALTON'S LYMPHOMA ASCITES

Fuente: Zenodo

Saved in:

Bibliographic Details
Main Author:	Rajashri Kale, Ashwini Ghortale, Mahesh Bhalsing
Format:	Recurso digital
Published:	Zenodo 2025
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

EXTRACTION AND PHYTOCHEMICAL ANALYSIS OF SECONDARY METABOLITES FROM ACHYRANTHES ASPERA LINN
by: Indian Journal of Science and Research
Published: (2026)

INTEGRATED IN VITRO AND IN SILICO DECODING OF THE ANTI-MDR ACTIVITY OF CASSIA FISTULA L. ETHANOLIC EXTRACT: A PROMISING PHYTO-THERAPEUTIC CANDIDATE AGAINST MULTIDRUG-RESISTANT ESCHERICHIA COLI AND STREPTOCOCCUS THERMOPHILUS
by: The Cancer Research Review
Published: (2026)

EVALUATION OF SKIN IRRITATION POTENTIAL OF PRAPUNNATBIJADI LEPA: A PRECLINICAL SAFETY ASSESSMENT IN WISTAR RATS
by: *1Dr. Neelam Valhekar, 2Dr. Nagnath Gangasagre
Published: (2026)

PHYTOCHEMICAL PROFILE AND EVALUATION OF PHOTOPROTECTIVE POTENTIAL OF Syringodium filiforme KÜTZING
by: Kethia L. González García
Published: (2017)

PHARMACOLOGICAL INSIGHTS INTO ANTIOXIDANT AND NOOTROPIC POTENTIAL OF ALANGIUM SALVIFOLIUM IN TRAUMATIC BRAIN INJURY: A PRECLINICAL REVIEW
by: Shahin Banu, et al.
Published: (2026)

FORMULATION AND EVALUATION OF ANTIMICROBIAL OINTMENT USING CASSIA TORA AND AERVA LANATA EXTRACT
by: Ranu Gunilal Katre*, Rashmi Kuthe, Mahesh Majumdar, Janvi Mohankar, Swati J. Tembhurne
Published: (2026)

85 | PATIENT‐DERIVED LYMPHOMA SPHEROIDS AS PRECLINICAL MODELS FOR PREDICTING PATIENT RESPONSES TO ADVANCED THERAPIES IN B‐NHL: EXAMPLE OF GLOFITAMAB IN FOLLICULAR LYMPHOMA
by: P. Marcoux, et al.
Published: (2025)

PHYTOCHEMICAL INVESTIGATION AND PHARMACOLOGICAL EVALUATION OF BUTEA MONOSPERMA ROOT EXTRACT FOR ANTI-ANXIETY ACTIVITY IN RATS
by: *1Mr. Pratik Laxman Kolte, 2Dr. Karna B. Khavane
Published: (2026)

RECENT DEVELOPMENT IN THE PHYTOCHEMICAL BASED NANO DRUG DELIVERY SYSTEM FOR WOUND HEALING AND SKIN REGENERATION
by: *Ashirwad Sawale, et al.
Published: (2025)

STUDY OF PHARMACOGNOSY AND PHYTOCHEMICAL SCREENING OF IMPERATA CYLINDRICA (L.) RAEUSCH
by: Annysa Ellycornia Silvyana, et al.
Published: (2024)

ANIMAL MODELS IN PRECLINICAL STUDIES FOR ANTIFERTILITY
by: B. V. Gokul Bal*, Dr. R. Manivannan, M. Bhuvanesh, M. Damodaran, P. Dharani Priya, S. Dhinesh Kumar
Published: (2026)

DALTON TREVISAN: CAPITU SEM ENIGMA
by: Adriana da Costa Teles
Published: (2020)

445 | ELA026, A MONOCLONAL ANTIBODY TARGETING SIRP‐EXPRESSING MYELOID CELLS AND T LYMPHOCYTES, DEMONSTRATES BROAD ANTI‐TUMOR ACTIVITY IN PATIENTS WITH LYMPHOMA
by: S. Iyer, et al.
Published: (2025)

22 | PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TUMOR SPREAD (Dmax) IN ADVANCED HODGKIN LYMPHOMA: ANCILLARY STUDY OF THE AHL2011 TRIAL
by: S. Kanoun, et al.
Published: (2025)

DALTON TREVISAN: NARRATIVA, CIDADE E URBANISMO
by: Clovis Ultramari
Published: (2018)

PELORIA IN VIOLA PRIMULAEFOLIA LINN
by: Detjen, L. R.
Published: (1920)

115 | THE BTK DEGRADER BGB‐16673 AND THE BCL2 INHIBITOR SONROTOCLAX SHOWS ANTI‐TUMOR ACTIVITY AS SINGLE AGENTS AND IN COMBINATION IN MARGINAL ZONE LYMPHOMA MODELS
by: A. J. Arribas, et al.
Published: (2025)

817 | ADVANTIG‐101: A PHASE 1B/2 STUDY OF OCIPERLIMAB (ANTI‐TIGIT) PLUS TISLELIZUMAB (ANTI‐PD‐1) OR RITUXIMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
by: Q. Cai, et al.
Published: (2025)

802 | A STUDY ON THE MECHANISM OF THE NOVEL HIGHLY SELECTIVE HDAC INHIBITOR PURINOSTAT MESYLATE IN DOUBLE‐HIT LYMPHOMA AND ITS THERAPEUTIC POTENTIAL COMBINATION WITH VENETOCLAX
by: J. Wang, et al.
Published: (2025)

BILIRUBIN NANOMEDICINES: PRECLINICAL ADVANCES, MECHANISTIC INSIGHTS, AND EMERGING TRANSLATIONAL PROSPECTS
by: Poonam, Deepak Prashar*, Randhir, Ruchika, Ritika, Shabnam, Shahniya
Published: (2026)

CORONARY CAMERAL FISTULA: CASE REPORT
by: Juan Sebastián Frías-Ordoñez
Published: (2018)

611 | TUMOR EVOLUTION AND IMMUNE MICROENVIRONMENT DYNAMICS IN PRIMARY AND RELAPSED MANTLE CELL LYMPHOMA
by: H. Wan, et al.
Published: (2025)

PHYTOCHEMICAL CHARACTERIZATION AND STANDARDIZATION OF TAMARINDUS INDICA
by: *1Waghmare Arati Anil, 2Gajbhare Dipti Shankar, 3Waghmare Komal Raju, 4Satpute Prajwal Ravindra, 5Warghade Yogita Shivaji
Published: (2026)

CONTRIBUTION TO THE PHYTOCHEMICAL STUDY AND CHEMICAL TESTS OF THE EXTRACTS OF Citrus limonium (LEMON) and Capsicum frutescens L. (CHILLI PEPPER)
by: L. C. C. FREIRE
Published: (2015)

334 | A PHASE I/II STUDY OF ORELABRUTINIB COMBINED WITH ANTI‐PD‐1 ANTIBODY AND FOTEMUSTINE FOR PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
by: W. Zhao, et al.
Published: (2025)

510 | THE ANTIBODY‐DEPENDENT CELLULAR CYTOTOXICITY AND METABOLIC TUMOR VOLUME BALANCE: A NOVEL PREDICTIVE MARKER FOR TUMOR RECURRENCE IN DIFFUSE LARGE B‐CELL LYMPHOMA
by: S. Rincon‐Lopez, et al.
Published: (2025)

FÍSTULA COLECISTO-UMBILICAL ESPONTÁNEA SECUNDARIA A COLECISTOLITIASIS
by: Freddy Miguel Ortiz Aparicio
Published: (2009)

231 | IMPACT OF RITUXIMAB EARLY ADMINISTRATION ON OUTCOMES IN ADVANCED STAGE LOW TUMOR BURDEN FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF PHASE III JCOG1411/FLORA STUDY
by: D. Maruyama, et al.
Published: (2025)

AN EMPIRICAL STUDY ON THE IMPACT OF TRAINING PROGRAMS ON EMPLOYEE UPSKILLING AND JOB PERFORMANCE
by: Pavithra S M, Dr. Ashwini P
Published: (2026)

347 | ANTI‐PD‐1 ANTIBODY (TISLELIZUMAB) COMBINED WITH R‐CHOP FOR THE TREATMENT OF PREVIOUSLY UNTREATED PRIMARY MEDIASTINAL B‐CELL LYMPHOMA: A PROSPECTIVE PHASE II STUDY
by: W. Shu juan, et al.
Published: (2025)

SEMANTIC PRIMING IN CHILDREN: AN EVENT-RELATED POTENTIAL (ERP) STUDY
by: Paula López-Alanís
Published: (2012)

PHYTOCHEMICAL AND PHARMACOLOGICAL EVALUATION OF ANTIEPILEPTIC ACTIVITY OF METHONNI
by: Papagatla Poli Reddy*, Boddu Harika
Published: (2026)

CARACTERIZACIÓN ANÁTOMO-CLÍNICA DE LA FÍSTULA FISURARIA
by: Cristóbal Suazo L.
Published: (2014)

463 | ANTI‐CD19 CAR‐T CELL THERAPY IN RELAPSED/REFRACTORY T‐CELL/HISTIOCYTE‐RICH LARGE B‐CELL LYMPHOMA: INSIGHTS FROM THE FRENCH DESCAR‐T REGISTRY, A LYSA STUDY
by: A. André, et al.
Published: (2025)

130 | TISLELIZUMAB, AN ANTI‐PD‐1 ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: FINAL ANALYSIS FROM THE LYSA PHASE 2 TIRHOL STUDY BGB‐A317‐210
by: H. Ghesquières, et al.
Published: (2025)

ANTIMICROBIAL AND CYTOTOXIC PROPERTIES OF PHYLLANTHUS NIRURI: A PHYTOCHEMICAL APPROACH
by: Parvathy Prasad*, et al.
Published: (2025)

485 | EXOSOMAL BCYRN1 IN NK/T—CELL LYMPHOMA: UNVEILING ITS ROLE IN MACROPHAGE POLARIZATION AND TUMOR PROGRESSION
by: L. Zeng, et al.
Published: (2025)

153 | HARNESSING SYSTEMIC INFLAMMATION WITH CIRCULATING TUMOR DNA IMPROVES SURVIVAL PREDICTION IN LARGE B‐CELL LYMPHOMA
by: S. Leppä, et al.
Published: (2025)

345 | PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: A MULTICENTRIC OBSERVATIONAL STUDY OF SPANISH LYMPHOMA GROUP GELTAMO
by: A. Cabero Martínez, et al.
Published: (2025)

579 | A SYSTEMATIC REVIEW AND META‐ANALYSIS OF LENALIDOMIDE AND ANTI‐CD20 MONOCLONAL ANTIBODY THERAPY IN FOLLICULAR LYMPHOMA
by: S. Matarasso, et al.
Published: (2025)